scholarly journals Cysteine dioxygenase 1 (CDO1) is differentially expressed in non-small cell lung cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Cysteine Dioxygenase ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Significant Differential Expression ◽  
Lung Cancers

Non-small cell lung cancer (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of the gene encoding cysteine dioxygenase 1, CDO1 (6), in tumors from patients with NSCLC. CDO1 may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.

scholarly journals Coding and non-coding RNAs produced at the RAMP2 locus are differentially expressed in non-small cell lung cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Significant Differential Expression ◽  
Lung Cancers ◽  
Rna Transcripts ◽  
Non Coding Rna

Non-small cell lung cancer (NSCLC) is a leading cause of death in the United States and worldwide (1, 2). We mined published microarray data (3, 4, 5) to discover genes associated with NSCLC. We identified significant differential expression of coding and non-coding RNA transcripts produced at the RAMP2 (6) locus in tumors from patients with NSCLC. RAMP2 may be of relevance to the initiation, progression or maintenance of non-small cell lung cancers.

scholarly journals Glycoprotein M6A is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Human Nsclc ◽  
Lower Expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that gene encoding glycoprotein M6A, GPM6A, was among those whose expression was most quantitatively different in human NSCLC tumors as compared to the lung. GPM6A expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of GPM6A in patient tumors was significantly associated with worse overall survival. GPM6A may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals RhoJ is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Human Nsclc ◽  
Lower Expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding RhoJ, the ras homolog family member J (RhoJ) among those whose expression was most quantitatively different in human NSCLC tumors as compared to the lung. RhoJ expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of RhoJ in patient tumors was significantly associated with worse overall survival. RhoJ may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals Significant Role of Nanoparticles as a Drug Delivery System for Cancer Treatment

2021 ◽  
pp. 383-423
Author(s):  
Alireza Heidari ◽  
Ricardo Gobato ◽  
Abhijit Mitra
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers ◽  
Dna Mutations ◽  
Phase 2 Clinical Trial ◽  
Keywords Cancer

According to the results of a global phase 2 clinical trial, the new drug sotorasib reduces tumor size and promises to improve and increase survival in patients with lung tumors caused by specific DNA mutations. It is designed to counteract the effects of mutations that are seen in about 13% of patients with non-small cell lung adenocarcinoma (a common type of lung cancer). The Food and Drug Administration (FDA) on May 28 approved the drug as a targeted treatment for patients with small cell lung cancer whose tumors express a specific mutation called G12C in the KRAS gene. Small cell lung cancer accounts for more than 80% of lung cancers. More than 200,000 new cases of non-small cell lung cancer are diagnosed in the United States each year. Keywords: Cancer; Cells; Tissues; Tumors; Prevention; Prognosis; Diagnosis; Imaging; Screening, Treatment; Management

scholarly journals Leucine-rich repeat neuronal 3, LRRN3, is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Leucine Rich Repeat ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Human Nsclc

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding the leucine-rich repeat neuronal 3, LRRN3, was among those whose expression was most different in human NSCLC tumors as compared to the lung. LRRN3 expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of LRRN3 in patient tumors was significantly associated with worse overall survival. LRRN3 may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals TCF21 is differentially expressed in non-small cell lung cancer.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Microarray Data ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Cancer Death ◽  
Small Cell Lung ◽  
Gene Encoding

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4, 5) to identify differentially expressed genes in NSCLC. We found that the gene encoding the transcription factor TCF21 was among the genes whose expression was most quantitatively different in tumors from patients with NSCLC as compared to the lung. TCF21 may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals The myocardial zonula adherens protein, MYZAP, is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Human Nsclc ◽  
Lower Expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding the myocardial zonula adherens protein, MYZAP, was among those whose expression was most different in human NSCLC tumors as compared to the lung. MYZAP expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of MYZAP in patient tumors was significantly associated with worse overall survival. MYZAP may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals Cadherin 5 is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Human Nsclc ◽  
Lower Expression

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding cadherin 5 (Cdh5) was among those whose expression was most quantitatively different in human NSCLC tumors as compared to the lung. Cdh5 expression levels were significantly decreased in NSCLC tumors as compared to the lung, and lower expression of Cdh5 in patient tumors was significantly associated with worse overall survival. Cdh5 may be important for initiation or progression of non-small cell lung cancer in humans.

scholarly journals Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer

2020 ◽  
Vol 13 (11) ◽  
pp. 374
Author(s):  
Lisa Mustachio ◽  
Jason Roszik
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Targeted Therapies ◽  
Treatment Strategies ◽  
The United States ◽  
Current Treatment ◽  
Small Cell ◽  
Small Cell Lung ◽  
Lung Cancers

Lung cancers contribute to the greatest number of cancer-related deaths worldwide and still pose challenges in response to current treatment strategies. Non-small cell lung cancer (NSCLC) accounts for over 85% of lung cancers diagnosed in the United States and novel therapeutics are needed for the treatment of this disease. First and second generation targeted therapies against specific mutated or rearranged oncogenes in NSCLCs show anti-tumor activity and also increase survival. However, many NSCLC patients eventually develop resistance to these therapies or do not properly respond if they have central nervous system metastases. Thus, this review summarizes recent developments and findings related to the generation of novel targeted therapies recently or currently being developed to tackle hurdles that prior therapies were not able to overcome.

scholarly journals Pyrroline-5-carboxylate reductase 1, PYCR1, is differentially expressed in non-small cell lung cancer and associates with patient survival.

2020 ◽  
Author(s):  
Shahan Mamoor
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
The United States ◽  
Small Cell ◽  
Differentially Expressed ◽  
Small Cell Lung ◽  
Gene Encoding ◽  
Carboxylate Reductase ◽  
Human Nsclc

Non-small cell lung cancer (NSCLC) is the leading cause of cancer death in the United States (1). We mined published microarray data (2, 3, 4) to identify differentially expressed genes in NSCLC. We found that the gene encoding pyrroline-5-carboxylate reductase 1, PYCR1, was among those whose expression was most quantitatively different in human NSCLC tumors as compared to the lung. PYCR1 expression levels were significantly increased in NSCLC tumors as compared to the lung, and higher expression of PYCR1 in patient tumors was significantly correlated with worse overall survival and decreased time to first progression. PYCR1 may be important for initiation or progression of non-small cell lung cancer in humans.

Sign in / Sign up

Export Citation Format

Share Document